Cabotegravir Patent Expiration
Cabotegravir was first introduced by Viiv Healthcare Co
Cabotegravir Patents
Given below is the list of patents protecting Cabotegravir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Apretude | US10927129 | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity | Apr 28, 2026 | Viiv Hlthcare |
| Apretude | US11224597 | Pharmaceutical compositions | Sep 15, 2031 | Viiv Hlthcare |
| Apretude | US8410103 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent | Apr 28, 2026 | Viiv Hlthcare |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳